Director Matthew Cohen granted 11,882 RSUs at Arrowhead Pharmaceuticals (ARWR)

Rhea-AI Filing Summary

Arrowhead Pharmaceuticals director Matthew Gregory Cohen received an equity award. On the grant dated 06/15/2026, he acquired 11,882 shares of Common Stock underlying restricted stock units at no cash cost. These units vest over three years, and following the grant he directly holds 11,882 shares.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Cohen Matthew Gregory

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	11,882	$0.00	--

Holdings After Transaction: Common Stock — 11,882 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

RSU shares granted: 11,882 shares Grant price per share: $0.00 per share Shares held after grant: 11,882 shares +1 more

4 metrics

RSU shares granted 11,882 shares Restricted stock units granted on 06/15/2026

Grant price per share $0.00 per share Equity award, no cash cost to insider

Shares held after grant 11,882 shares Total non-derivative holdings following transaction

Vesting period 3 years RSUs vest over three years from 06/15/2026 grant date

Key Terms

restricted stock units, grant date, Grant, award, or other acquisition

3 terms

restricted stock units financial

"Represents shares underlying restricted stock units with a grant date 06/15/2026, which will vest over three years."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

grant date financial

"Represents shares underlying restricted stock units with a grant date 06/15/2026, which will vest over three years."

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

Grant, award, or other acquisition financial

"transaction_code_description": "Grant, award, or other acquisition""

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cohen Matthew Gregory

(Last) (First) (Middle)

177 EAST COLORADO BLVD STE 700

(Street)

PASADENA CALIFORNIA 91105

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
ARROWHEAD PHARMACEUTICALS, INC. [ ARWR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/15/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/15/2026		A		11,882(1)	A	$0	11,882	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares underlying restricted stock units with a grant date 06/15/2026, which will vest over three years.

Remarks:

	/s/Matthew Gregory Cohen	06/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Arrowhead Pharmaceuticals (ARWR) report for Matthew Gregory Cohen?

Arrowhead Pharmaceuticals reported that director Matthew Gregory Cohen received a grant of 11,882 shares of Common Stock underlying restricted stock units on 06/15/2026. The award was recorded at a price of $0.00 per share as a compensation-related equity grant.

Was Matthew Gregory Cohen’s Arrowhead (ARWR) Form 4 transaction a stock purchase or a grant?

The Form 4 shows a grant, not an open-market purchase. Cohen acquired 11,882 shares through restricted stock units coded as transaction type “A,” which indicates a grant, award, or other acquisition provided as equity compensation rather than a cash-funded share purchase.

What are the vesting terms of Matthew Gregory Cohen’s 11,882 Arrowhead (ARWR) restricted stock units?

The 11,882 restricted stock units granted to Matthew Gregory Cohen vest over three years from the 06/15/2026 grant date. This means the underlying Common Stock is delivered gradually, aligning his compensation with longer-term company performance and continued board service during that period.

How many Arrowhead (ARWR) shares does Matthew Gregory Cohen hold after this Form 4 transaction?

After the reported Form 4 transaction, Matthew Gregory Cohen directly holds 11,882 shares of Arrowhead Pharmaceuticals Common Stock. This total reflects the newly granted restricted stock unit award, as disclosed in the filing’s “shares following transaction” field for his non-derivative holdings.